Copyright © 2008 S. L. Spinelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. D. L. Bhatt, P. G. Steg, and E. M. Ohman, et al., “International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis,” Journal of the American Medical Association, vol. 295, no. 2, pp. 180–189, 2006. View at Publisher · View at Google Scholar · View at PubMed
2. A. J. Lusis, “Atherosclerosis,” Nature, vol. 407, no. 6801, pp. 233–241, 2000. View at Publisher · View at Google Scholar · View at PubMed
3. R. P. Phipps, “Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 13, pp. 6930–6932, 2000. View at Publisher · View at Google Scholar
4. R. P. Phipps, L. Koumas, E. Leung, S. Y. Reddy, T. Blieden, and J. Kaufman, “The CD40-CD40 ligand system: a potential therapeutic target in atherosclerosis,” Current Opinion in Investigational Drugs, vol. 2, no. 6, pp. 773–777, 2001.
5. D. M. Ray, S. L. Spinelli, J. J. O'Brien, N. Blumberg, and R. P. Phipps, “Platelets as a novel target for PPAR$\gamma$ ligands: implications for inflammation, diabetes, and cardiovascular disease,” BioDrugs, vol. 20, no. 4, pp. 231–241, 2006. View at Publisher · View at Google Scholar
6. R. Ross, “Atherosclerosis—an inflammatory disease,” The New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at Publisher · View at Google Scholar
7. S. Danese, C. de la Motte, and A. Sturm, et al., “Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients,” Gastroenterology, vol. 124, no. 5, pp. 1249–1264, 2003. View at Publisher · View at Google Scholar
8. T. Smith, G. Dhunnoo, I. Mohan, and V. Charlton-Menys, “A pilot study showing an association between platelet hyperactivity and the severity of peripheral arterial disease,” Platelets, vol. 18, no. 4, pp. 245–248, 2007. View at Publisher · View at Google Scholar · View at PubMed
9. K. T. Tan and G. Y. H. Lip, “The potential role of platelet microparticles in atherosclerosis,” Thrombosis and Haemostasis, vol. 94, no. 3, pp. 488–492, 2005. View at Publisher · View at Google Scholar · View at PubMed
10. A. I. Vinik, T. Erbas, T. S. Park, R. Nolan, and G. L. Pittenger, “Platelet dysfunction in type 2 diabetes,” Diabetes Care, vol. 24, no. 8, pp. 1476–1485, 2001. View at Publisher · View at Google Scholar
11. Y. J. Lee, W. Jy, and L. L. Horstman, et al., “Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multi-infarct dementias,” Thrombosis Research, vol. 72, no. 4, pp. 295–304, 1993. View at Publisher · View at Google Scholar
12. S. Nomura, S. Uehata, S. Saito, K. Osumi, Y. Ozeki, and Y. Kimura, “Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome,” Thrombosis and Haemostasis, vol. 89, no. 3, pp. 506–512, 2003.
13. F. Zeiger, S. Stephan, G. Hoheisel, D. Pfeiffer, C. Ruehlmann, and M. Koksch, “P-selectin expression, platelet aggregates, and platelet-derived microparticle formation are increased in peripheral arterial disease,” Blood Coagulation and Fibrinolysis, vol. 11, no. 8, pp. 723–728, 2000. View at Publisher · View at Google Scholar
14. J. A. Coppinger, G. Cagney, and S. Toomey, et al., “Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions,” Blood, vol. 103, no. 6, pp. 2096–2104, 2004. View at Publisher · View at Google Scholar · View at PubMed
15. A. García, S. P. Watson, R. A. Dwek, and N. Zitzmann, “Applying proteomics technology to platelet research,” Mass Spectrometry Reviews, vol. 24, no. 6, pp. 918–930, 2005. View at Publisher · View at Google Scholar · View at PubMed
16. J. P. McRedmond, S. D. Park, and D. F. Reilly, et al., “Integration of proteomics and genomics in platelets: a profile of platelet proteins and platelet-specific genes,” Molecular & Cellular Proteomics, vol. 3, no. 2, pp. 133–144, 2004. View at Publisher · View at Google Scholar · View at PubMed
17. S. Kersten, B. Desvergne, and W. Wahli, “Roles of PPARs in health and disease,” Nature, vol. 405, no. 6785, pp. 421–424, 2000. View at Publisher · View at Google Scholar · View at PubMed
18. H. Inoue, X.-F. Jiang, T. Katayama, S. Osada, K. Umesono, and S. Namura, “Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor $\alpha$ in mice,” Neuroscience Letters, vol. 352, no. 3, pp. 203–206, 2003. View at Publisher · View at Google Scholar
19. “Thiazolidinediones and cardiovascular disease,” The Medical Letter on Drugs and Therapeutics, vol. 49, no. 1265, pp. 57–58, 2007.
20. S. R. Patel, J. H. Hartwig, and J. E. Italiano Jr., “The biogenesis of platelets from megakaryocyte proplatelets,” Journal of Clinical Investigation, vol. 115, no. 12, pp. 3348–3354, 2005. View at Publisher · View at Google Scholar · View at PubMed
21. M. M. Denis, N. D. Tolley, and M. Bunting, et al., “Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets,” Cell, vol. 122, no. 3, pp. 379–391, 2005. View at Publisher · View at Google Scholar · View at PubMed
22. D. V. Gnatenko, J. J. Dunn, S. R. McCorkle, D. Weissmann, P. L. Perrotta, and W. F. Bahou, “Transcript profiling of human platelets using microarray and serial analysis of gene expression,” Blood, vol. 101, no. 6, pp. 2285–2293, 2003. View at Publisher · View at Google Scholar · View at PubMed
23. N. Kieffer, J. Guichard, J.-P. Farcet, W. Vainchenker, and J. Breton-Gorius, “Biosynthesis of major platelet proteins in human blood platelets,” European Journal of Biochemistry, vol. 164, no. 1, pp. 189–195, 1987. View at Publisher · View at Google Scholar
24. A. S. Weyrich, D. A. Dixon, and R. Pabla, et al., “Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 10, pp. 5556–5561, 1998. View at Publisher · View at Google Scholar
25. S. Lindemann, N. D. Tolley, and D. A. Dixon, et al., “Activated platelets mediate inflammatory signaling by regulated interleukin 1$\beta$ synthesis,” Journal of Cell Biology, vol. 154, no. 3, pp. 485–490, 2001. View at Publisher · View at Google Scholar · View at PubMed
26. H. Brogren, L. Karlsson, M. Andersson, L. Wang, D. Erlinge, and S. Jern, “Platelets synthesize large amounts of active plasminogen activator inhibitor 1,” Blood, vol. 104, no. 13, pp. 3943–3948, 2004. View at Publisher · View at Google Scholar · View at PubMed
27. M. Camera, M. Frigerio, and V. Toschi, et al., “Platelet activation induces cell-surface immunoreactive tissue factor expression, which is modulated differently by antiplatelet drugs,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 9, pp. 1690–1696, 2003. View at Publisher · View at Google Scholar · View at PubMed
28. H. Schwertz, N. D. Tolley, and J. M. Foulks, et al., “Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenecity of human platelets,” Journal of Experimental Medicine, vol. 203, no. 11, pp. 2433–2440, 2006. View at Publisher · View at Google Scholar · View at PubMed
29. O. Panes, V. Matus, C. G. Sáez, T. Quiroga, J. Pereira, and D. Mezzano, “Human platelets synthesize and express functional tissue factor,” Blood, vol. 109, no. 12, pp. 5242–5250, 2007. View at Publisher · View at Google Scholar · View at PubMed
30. J. M. Cholette, N. Blumberg, R. P. Phipps, M. P. McDermott, K. F. Gettings, and N. P. Lerner, “Developmental changes in soluble CD40 ligand,” Journal of Pediatrics. In Press. View at Publisher · View at Google Scholar
31. P. Libby, “Vascular biology of atherosclerosis: overview and state of the art,” The American Journal of Cardiology, vol. 91, no. 3, supplement 1, pp. 3–6, 2003. View at Publisher · View at Google Scholar
32. P. Aukrust, F. Müller, and T. Ueland, et al., “Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes,” Circulation, vol. 100, no. 6, pp. 614–620, 1999.
33. F. Cipollone, A. Mezzetti, and E. Porreca, et al., “Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy,” Circulation, vol. 106, no. 4, pp. 399–402, 2002. View at Publisher · View at Google Scholar
34. C. Heeschen, S. Dimmeler, and C. W. Hamm, et al., “Soluble CD40 ligand in acute coronary syndromes,” The New England Journal of Medicine, vol. 348, no. 12, pp. 1104–1111, 2003. View at Publisher · View at Google Scholar · View at PubMed
35. R. P. Phipps, J. Kaufman, and N. Blumberg, “Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion,” The Lancet, vol. 357, no. 9273, pp. 2023–2024, 2001. View at Publisher · View at Google Scholar
36. C. van Kooten and J. Banchereau, “CD40-CD40 ligand,” Journal of Leukocyte Biology, vol. 67, no. 1, pp. 2–17, 2000.
37. J. Kaufman, S. L. Spinelli, E. Schultz, N. Blumberg, and R. P. Phipps, “Release of biologically active CD154 during collection and storage of platelet concentrates prepared for transfusion,” Journal of Thrombosis and Haemostasis, vol. 5, no. 4, pp. 788–796, 2007. View at Publisher · View at Google Scholar · View at PubMed
38. C. Stumpf, C. Lehner, and S. Eskafi, et al., “Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure,” European Journal of Heart Failure, vol. 5, no. 5, pp. 629–637, 2003. View at Publisher · View at Google Scholar
39. N. Varo, D. Vicent, and P. Libby, et al., “Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones,” Circulation, vol. 107, no. 21, pp. 2664–2669, 2003. View at Publisher · View at Google Scholar · View at PubMed
40. R. J. Noelle, “CD40 and its ligand in host defense,” Immunity, vol. 4, no. 5, pp. 415–419, 1996. View at Publisher · View at Google Scholar
41. P. André, K. S. Srinivasa Prasad, and C. V. Denis, et al., “CD40L stabilizes arterial thrombi by a ${\beta }_3$ integrin-dependent mechanism,” Nature Medicine, vol. 8, no. 3, pp. 247–252, 2002. View at Publisher · View at Google Scholar · View at PubMed
42. S. A. Kliewer, B. M. Forman, and B. Blumberg, et al., “Differential expression and activation of a family of murine peroxisome proliferator-activated receptors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 15, pp. 7355–7359, 1994. View at Publisher · View at Google Scholar
43. K. S. Srinivasa Prasad, P. André, M. He, M. Bao, J. Manganello, and D. R. Phillips, “Soluble CD40 ligand induces ${\beta }_3$ integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 21, pp. 12367–12371, 2003. View at Publisher · View at Google Scholar · View at PubMed
44. L. L. Horstman, W. Jy, J. J. Jimenez, C. Bidot, and Y. S. Ahn, “New horizons in the analysis of circulating cell-derived microparticles,” Keio Journal of Medicine, vol. 53, no. 4, pp. 210–230, 2004. View at Publisher · View at Google Scholar
45. J. Simak and M. P. Gelderman, “Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers,” Transfusion Medicine Reviews, vol. 20, no. 1, pp. 1–26, 2006. View at Publisher · View at Google Scholar · View at PubMed
46. A. P. Bode, H. Sandberg, F. A. Dombrose, and B. R. Lentz, “Association of factor V activity with membranous vesicles released from human platelets: requirement for platelet stimulation,” Thrombosis Research, vol. 39, no. 1, pp. 49–61, 1985. View at Publisher · View at Google Scholar
47. P. Siljander, O. Carpen, and R. Lassila, “Platelet-derived microparticles associate with fibrin during thrombosis,” Blood, vol. 87, no. 11, pp. 4651–4663, 1996.
48. S. Nomura, N. N. Tandon, T. Nakamura, J. Cone, S. Fukuhara, and J. Kambayashi, “High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells,” Atherosclerosis, vol. 158, no. 2, pp. 277–287, 2001. View at Publisher · View at Google Scholar
49. S. F. Mause, P. von Hundelshausen, A. Zernecke, R. R. Koenen, and C. Weber, “Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 7, pp. 1512–1518, 2005. View at Publisher · View at Google Scholar · View at PubMed
50. O. P. Barry, D. Praticò, R. C. Savani, and G. A. FitzGerald, “Modulation of monocyte-endothelial cell interactions by platelet microparticles,” Journal of Clinical Investigation, vol. 102, no. 1, pp. 136–144, 1998. View at Publisher · View at Google Scholar
51. T. Scholz, U. Temmler, S. Krause, S. Heptinstall, and W. Lösche, “Transfer of tissue factor from platelets to monocytes: role of platelet-derived microvesicles and CD62P,” Thrombosis and Haemostasis, vol. 88, no. 6, pp. 1033–1038, 2002.
52. M. J. VanWijk, E. VanBavel, A. Sturk, and R. Nieuwland, “Microparticles in cardiovascular diseases,” Cardiovascular Research, vol. 59, no. 2, pp. 277–287, 2003. View at Publisher · View at Google Scholar
53. M. Diamant, R. Nieuwland, R. F. Pablo, A. Sturk, J. W. A. Smit, and J. K. Radder, “Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus,” Circulation, vol. 106, no. 19, pp. 2442–2447, 2002. View at Publisher · View at Google Scholar
54. A. Janowska-Wieczorek, M. Majka, and J. Kijowski, et al., “Platelet-derived microparticles bind to hematopoietic stem/progenitor cells and enhance their engraftment,” Blood, vol. 98, no. 10, pp. 3143–3149, 2001. View at Publisher · View at Google Scholar
55. H. Duez, J.-C. Fruchart, and B. Staels, “PPARs in inflammation, atherosclerosis and thrombosis,” Journal of Cardiovascular Risk, vol. 8, no. 4, pp. 187–194, 2001. View at Publisher · View at Google Scholar
56. J. Padilla, K. Kaur, S. G. Harris, and R. P. Phipps, “PPAR-$\gamma$-mediated regulation of normal and malignant B lineage cells,” Annals of the New York Academy of Sciences, vol. 905, pp. 97–109, 2000.
57. I. Issemann and S. Green, “Cloning of novel members of the steroid hormone receptor superfamily,” Journal of Steroid Biochemistry and Molecular Biology, vol. 40, no. 1–3, pp. 263–269, 1991. View at Publisher · View at Google Scholar
58. O. Braissant, F. Foufelle, C. Scotto, M. Dauça, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-$\alpha$, -$\beta$, and -$\gamma$ in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996. View at Publisher · View at Google Scholar
59. S. G. Harris and R. P. Phipps, “The nuclear receptor PPAR $\gamma$ is expressed by mouse T lymphocytes and PPAR $\gamma$ agonists induce apoptosis,” European Journal of Immunology, vol. 31, no. 4, pp. 1098–1105, 2001. View at Publisher · View at Google Scholar
60. D. M. Ray, S. H. Bernstein, and R. P. Phipps, “Human multiple myeloma cells express peroxisome proliferator-activated receptor $\gamma$ and undergo apoptosis upon exposure to PPAR$\gamma$ ligands,” Clinical Immunology, vol. 113, no. 2, pp. 203–213, 2004. View at Publisher · View at Google Scholar · View at PubMed
61. D. Auboeuf, J. Rieusset, and L. Fajas, et al., “Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-$\alpha$ in humans: no alteration in adipose tissue of obese and NIDDM patients,” Diabetes, vol. 46, no. 8, pp. 1319–1327, 1997. View at Publisher · View at Google Scholar
62. U. Seedorf and J. Aberle, “Emerging roles of PPAR$\delta$ in metabolism,” Biochimica et Biophysica Acta, vol. 1771, no. 9, pp. 1125–1131, 2007. View at Publisher · View at Google Scholar · View at PubMed
63. F. Akbiyik, D. M. Ray, K. F. Gettings, N. Blumberg, C. W. Francis, and R. P. Phipps, “Human bone marrow megakaryocytes and platelets express PPAR$\gamma$, and PPAR$\gamma$ agonists blunt platelet release of CD40 ligand and thromboxanes,” Blood, vol. 104, no. 5, pp. 1361–1368, 2004. View at Publisher · View at Google Scholar · View at PubMed
64. F. Y. Ali, S. J. Davidson, and L. A. Moraes, et al., “Role of nuclear receptor signaling in platelets: antithrombotic effects of PPAR$\beta$,” The FASEB Journal, vol. 20, no. 2, pp. 326–328, 2006. View at Publisher · View at Google Scholar · View at PubMed
65. S. A. Kliewer, K. Umesono, D. J. Noonan, R. A. Heyman, and R. M. Evans, “Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors,” Nature, vol. 358, no. 6389, pp. 771–774, 1992. View at Publisher · View at Google Scholar · View at PubMed
66. A. I. Shulman and D. J. Mangelsdorf, “Retinoid X receptor heterodimers in the metabolic syndrome,” The New England Journal of Medicine, vol. 353, no. 6, pp. 604–615, 2005. View at Publisher · View at Google Scholar · View at PubMed
67. J. Plutzky, “Inflammation in atherosclerosis and diabetes mellitus,” Reviews in Endocrine and Metabolic Disorders, vol. 5, no. 3, pp. 255–259, 2004. View at Publisher · View at Google Scholar · View at PubMed
68. N. Marx, H. Duez, J.-C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells,” Circulation Research, vol. 94, no. 9, pp. 1168–1178, 2004. View at Publisher · View at Google Scholar · View at PubMed
69. G. Rizzo and S. Fiorucci, “PPARs and other nuclear receptors in inflammation,” Current Opinion in Pharmacology, vol. 6, no. 4, pp. 421–427, 2006. View at Publisher · View at Google Scholar · View at PubMed
70. T. Sher, H. F. Yi, O. W. McBride, and F. J. Gonzalez, “cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor,” Biochemistry, vol. 32, no. 21, pp. 5598–5604, 1993. View at Publisher · View at Google Scholar
71. N. Sambandam, D. Morabito, C. Wagg, B. N. Finck, D. P. Kelly, and G. D. Lopaschuk, “Chronic activation of PPAR$\alpha$ is detrimental to cardiac recovery after ischemia,” American Journal of Physiology, vol. 290, no. 1, pp. H87–H95, 2006. View at Publisher · View at Google Scholar · View at PubMed
72. T. H. Thatcher, P. J. Sime, and R. K. Barth, “Sensitivity to bleomycin-induced lung injury is not moderated by an antigen-limited T-cell repertoire,” Experimental Lung Research, vol. 31, no. 7, pp. 685–700, 2005. View at Publisher · View at Google Scholar · View at PubMed
73. H. F. Lakatos, T. H. Thatcher, R. M. Kottmann, T. M. Garcia, R. P. Phipps, and P. J. Sime, “The role of PPARs in lung fibrosis,” PPAR Research, vol. 2007, Article ID 71323, 10 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
74. J. Auwerx, K. Schoonjans, J.-C. Fruchart, and B. Staels, “Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects,” Journal of atherosclerosis and thrombosis, vol. 3, no. 2, pp. 81–89, 1996.
75. J. D. Brown and J. Plutzky, “Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets,” Circulation, vol. 115, no. 4, pp. 518–533, 2007. View at Publisher · View at Google Scholar · View at PubMed
76. Y.-X. Wang, C.-H. Lee, and S. Tiep, et al., “Peroxisome-proliferator-activated receptor $\delta$ activates fat metabolism to prevent obesity,” Cell, vol. 113, no. 2, pp. 159–170, 2003. View at Publisher · View at Google Scholar
77. G. D. Barish, V. A. Narkar, and R. M. Evans, “PPAR$\delta$: a dagger in the heart of the metabolic syndrome,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 590–597, 2006. View at Publisher · View at Google Scholar · View at PubMed
78. C.-H. Lee, A. Chawla, N. Urbiztondo, D. Liao, W. A. Boisvert, and R. M. Evans, “Transcriptional repression of atherogenic inflammation: modulation by PPAR$\delta$,” Science, vol. 302, no. 5644, pp. 453–457, 2003. View at Publisher · View at Google Scholar · View at PubMed
79. H. Lim and S. K. Dey, “Minireview: a novel pathway of prostacyclin signaling—hanging out with nuclear receptors,” Endocrinology, vol. 143, no. 9, pp. 3207–3210, 2002. View at Publisher · View at Google Scholar
80. B. M. Forman, J. Chen, and R. M. Evans, “Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors $\alpha$ and $\delta$,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4312–4317, 1997. View at Publisher · View at Google Scholar
81. G. Anfossi, P. Massucco, E. Mularoni, F. Cavalot, L. Mattiello, and M. Trovati, “Organic nitrates and compounds that increase intraplatelet cyclic guanosine monophosphate (cGMP) levels enhance the antiaggregating effects of the stable prostacyclin analogue iloprost,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 49, no. 5, pp. 839–845, 1993. View at Publisher · View at Google Scholar
82. R. J. Gryglewski, “Interactions between nitric oxide and prostacyclin,” Seminars in Thrombosis and Hemostasis, vol. 19, no. 2, pp. 158–166, 1993. View at Publisher · View at Google Scholar
83. P. S. Macdonald, M. A. Read, and G. J. Dusting, “Synergistic inhibition of platelet aggregation by endothelium-derived relaxing factor and prostacyclin,” Thrombosis Research, vol. 49, no. 5, pp. 437–449, 1988. View at Publisher · View at Google Scholar
84. M. W. Radomski, R. M. Palmer, and S. Moncada, “The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide,” British Journal of Pharmacology, vol. 92, no. 3, pp. 639–646, 1987.
85. M. Spiecker, H. Darius, and J. Meyer, “Synergistic platelet antiaggregatory effects of the adenylate cyclase activator iloprost and the guanylate cyclase activating agent SIN-1 in vivo,” Thrombosis Research, vol. 70, no. 5, pp. 405–415, 1993. View at Publisher · View at Google Scholar
86. P. S. Lidbury, E. Antunes, G. de Nucci, and J. R. Vane, “Interactions of iloprost and sodium nitroprusside on vascular smooth muscle and platelet aggregation,” British Journal of Pharmacology, vol. 98, no. 4, pp. 1275–1280, 1989.
87. R. Katzenschlager, K. Weiss, W. Rogatti, B. A. Peskar, and H. Sinzinger, “Synergism between ${\text{PGE}}_1$-metabolites (13,14-dihydro-prostaglandin ${\text{E}}_{\text{1}}$, 15-keto prostaglandin ${\text{E}}_{\text{1}}$, 15-keto-13,14-Dihydro-prostaglandin ${\text{E}}_{\text{1}}$) and nitric oxide (NO) on platelet aggregation,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 45, no. 3, pp. 207–210, 1992. View at Publisher · View at Google Scholar
88. R. Katzenschlager, K. Weiss, W. Rogatti, M. Stelzeneder, and H. Sinzinger, “Interaction between prostaglandin ${\text{E}}_1$ and nitric oxide (NO),” Thrombosis Research, vol. 62, no. 4, pp. 299–304, 1991. View at Publisher · View at Google Scholar
89. F. Y. Ali, K. Egan, and G. A. FitzGerald, et al., “Role of prostacyclin versus peroxisome proliferator-activated receptor $\beta$ receptors in prostacyclin sensing by lung fibroblasts,” American Journal of Respiratory Cell and Molecular Biology, vol. 34, no. 2, pp. 242–246, 2006. View at Publisher · View at Google Scholar · View at PubMed
90. T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke, “The PPARs: from orphan receptors to drug discovery,” Journal of Medicinal Chemistry, vol. 43, no. 4, pp. 527–550, 2000. View at Publisher · View at Google Scholar
91. J. Padilla, E. Leung, and R. P. Phipps, “Human B lymphocytes and B lymphomas express PPAR-$\gamma$ and are killed by PPAR-$\gamma$ agonists,” Clinical Immunology, vol. 103, no. 1, pp. 22–33, 2002. View at Publisher · View at Google Scholar · View at PubMed
92. D. Kelly, J. I. Campbell, and T. P. King, et al., “Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shutting of PPAR-$\gamma$ and ReIA,” Nature Immunology, vol. 5, no. 1, pp. 104–112, 2004. View at Publisher · View at Google Scholar · View at PubMed
93. Y. Zhu, C. Qi, and J. R. Korenberg, et al., “Structural organization of mouse peroxisome proliferator-activated receptor $\gamma$ (mPPAR$\gamma$) gene: alternative promoter use and different splicing yield two mPPAR$\gamma$ isoforms,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 17, pp. 7921–7925, 1995. View at Publisher · View at Google Scholar
94. L. Fajas, D. Auboeuf, and E. Raspé, et al., “The organization, promoter analysis, and expression of the human PPAR$\gamma$ gene,” Journal of Biological Chemistry, vol. 272, no. 30, pp. 18779–18789, 1997. View at Publisher · View at Google Scholar
95. M. Ricote, J. Huang, and L. Fajas, et al., “Expression of the peroxisome proliferator-activated receptor $\gamma$ (PPAR$\gamma$) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 13, pp. 7614–7619, 1998. View at Publisher · View at Google Scholar
96. K. Iijima, M. Yoshizumi, and J. Ako, et al., “Expression of peroxisome proliferator-activated receptor $\gamma$ (PPAR$\gamma$) in rat aortic smooth muscle cells,” Biochemical and Biophysical Research Communications, vol. 247, no. 2, pp. 353–356, 1998. View at Publisher · View at Google Scholar · View at PubMed
97. A. Nencioni, F. Grünebach, A. Zobywlaski, C. Denzlinger, W. Brugger, and P. Brossart, “Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor $\gamma$,” Journal of Immunology, vol. 169, no. 3, pp. 1228–1235, 2002.
98. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-$\gamma$ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Publisher · View at Google Scholar · View at PubMed
99. L. Michalik, B. Desvergne, and W. Wahli, “Peroxisome-proliferator-activated receptors and cancers: complex stories,” Nature Reviews Cancer, vol. 4, no. 1, pp. 61–70, 2004. View at Publisher · View at Google Scholar · View at PubMed
100. S. G. Harris, J. Padilla, L. Koumas, D. M. Ray, and R. P. Phipps, “Prostaglandins as modulators of immunity,” Trends in Immunology, vol. 23, no. 3, pp. 144–150, 2002. View at Publisher · View at Google Scholar
101. A. von Knethen, M. Soller, and N. Tzieply, et al., “PPAR$\gamma$1 attenuates cytosol to membrane translocation of PKC$\alpha$ to desensitize monocytes/macrophages,” Journal of Cell Biology, vol. 176, no. 5, pp. 681–694, 2007. View at Publisher · View at Google Scholar · View at PubMed
102. S. W. Chung, B. Y. Kang, and S. H. Kim, et al., “Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-$\gamma$ and nuclear factor-$\kappa$B,” Journal of Biological Chemistry, vol. 275, no. 42, pp. 32681–32687, 2000. View at Publisher · View at Google Scholar · View at PubMed
103. F. Chen, V. Castranova, X. Shi, and L. M. Demers, “New insights into the role of nuclear factor-$\kappa$B, a ubiquitous transcription factor in the initiation of diseases,” Clinical Chemistry, vol. 45, no. 1, pp. 7–17, 1999.
104. L. A. Moraes, K. E. Swales, and J. A. Wray, et al., “Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets,” Blood, vol. 109, no. 9, pp. 3741–3744, 2007. View at Publisher · View at Google Scholar · View at PubMed
105. D. M. Ray, S. L. Spinelli, and S. J. Pollock, et al., “Peroxisome proliferator-activated receptor $\gamma$ and the retinoid X receptor transcription factors are released from activated human platelets and are shed in microparticles,” Thrombosis and Haemostasis, vol. 101, 2008. View at Publisher · View at Google Scholar · View at PubMed
106. V. Pasceri, H. D. Wu, J. T. Willerson, and E. T. H. Yeh, “Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-$\gamma$ activators,” Circulation, vol. 101, no. 3, pp. 235–238, 2000.
107. K. Goya, S. Sumitani, and M. Otsuki, et al., “The thiazolidinedione drug troglitazone up-regulates nitric oxide synthase expression in vascular endothelial cells,” Journal of Diabetes and its Complications, vol. 20, no. 5, pp. 336–342, 2006. View at Publisher · View at Google Scholar · View at PubMed
108. G. Anfossi and M. Trovati, “Pathophysiology of platelet resistance to anti-aggregating agents in insulin resistance and type 2 diabetes: implications for anti-aggregating therapy,” Cardiovascular and Hematological Agents in Medicinal Chemistry, vol. 4, no. 2, pp. 111–128, 2006. View at Publisher · View at Google Scholar
109. I. Juhan-Vague, P. E. Morange, and M.-C. Alessi, “The insulin resistance syndrome: implications for thrombosis and cardiovascular disease,” Pathophysiology of Haemostasis and Thrombosis, vol. 32, no. 5-6, pp. 269–273, 2002. View at Publisher · View at Google Scholar · View at PubMed
110. D. J. Schneider, “Abnormalities of coagulation, platelet function, and fibrinolysis associated with syndromes of insulin resistance,” Coronary Artery Disease, vol. 16, no. 8, pp. 473–476, 2005. View at Publisher · View at Google Scholar
111. M. Trovati and G. Anfossi, “Mechanisms involved in platelet hyperactivation and platelet-endothelium interrelationships in diabetes mellitus,” Current Diabetes Reports, vol. 2, no. 4, pp. 316–322, 2002. View at Publisher · View at Google Scholar
112. M. Trovati and G. Anfossi, “Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function,” Journal of Diabetes and Its Complications, vol. 16, no. 1, pp. 35–40, 2002. View at Publisher · View at Google Scholar
113. W. R. Oliver Jr., J. L. Shenk, and M. R. Snaith, et al., “A selective peroxisome proliferator-activated receptor $\delta$ agonist promotes reverse cholesterol transport,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 9, pp. 5306–5311, 2001. View at Publisher · View at Google Scholar · View at PubMed
114. P. Libby, P. M. Ridker, and A. Maseri, “Inflammation and atherosclerosis,” Circulation, vol. 105, no. 9, pp. 1135–1143, 2002. View at Publisher · View at Google Scholar
115. S. Lindemann, B. Krämer, P. Seizer, and M. Gawaz, “Platelets, inflammation and atherosclerosis,” Journal of Thrombosis and Haemostasis, vol. 5, supplement 1, pp. 203–211, 2007. View at Publisher · View at Google Scholar · View at PubMed
116. Z. M. Dong, S. M. Chapman, A. A. Brown, P. S. Frenette, R. O. Hynes, and D. D. Wagner, “The combined role of P- and E-selectins in atherosclerosis,” Journal of Clinical Investigation, vol. 102, no. 1, pp. 145–152, 1998. View at Publisher · View at Google Scholar
117. Y. Huo, A. Schober, and S. B. Forlow, et al., “Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E,” Nature Medicine, vol. 9, no. 1, pp. 61–67, 2002. View at Publisher · View at Google Scholar · View at PubMed
118. K. Daub, H. Langer, and P. Seizer, et al., “Platelets induce differentiation of human $\text{CD}{34}^{+}$ progenitor cells into foam cells and endothelial cells,” The FASEB Journal, vol. 20, no. 14, pp. 2559–2561, 2006. View at Publisher · View at Google Scholar · View at PubMed
119. S. Massberg, K. Brand, and S. Grüner, et al., “A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation,” Journal of Experimental Medicine, vol. 196, no. 7, pp. 887–896, 2002. View at Publisher · View at Google Scholar
120. S. Massberg, K. Schürzinger, and M. Lorenz, et al., “Platelet adhesion via glycoprotein IIb integrin is critical for atheroprogression and focal cerebral ischemia: an in vivo study in mice lacking glycoprotein IIb,” Circulation, vol. 112, no. 8, pp. 1180–1188, 2005. View at Publisher · View at Google Scholar · View at PubMed
121. T. Bombeli, B. R. Schwartz, and J. M. Harlan, “Adhesion of activated platelets to endothelial cells: evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), ${\alpha }_{\text{v}}{\beta }_3$ integrin, and GPIb$\alpha$,” Journal of Experimental Medicine, vol. 187, no. 3, pp. 329–339, 1998. View at Publisher · View at Google Scholar
122. M. Gawaz, F.-J. Neumann, and T. Dickfeld, et al., “Vitronectin receptor $\left({\alpha }_v{\beta }_3\right)$ mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction,” Circulation, vol. 96, no. 6, pp. 1809–1818, 1997.
123. M. Gawaz, F.-J. Neumann, I. Ott, A. Schiessler, and A. Schömig, “Platelet function in acute myocardial infarction treated with direct angioplasty,” Circulation, vol. 93, no. 2, pp. 229–237, 1996.
124. H. Langer, A. E. May, and K. Daub, et al., “Adherent platelets recruit and induce differentiation of murine embryonic endothelial progenitor cells to mature endothelial cells in vitro,” Circulation Research, vol. 98, no. 2, pp. e2–e10, 2006. View at Publisher · View at Google Scholar · View at PubMed
125. D. M. Jans, W. Martinet, and M. Fillet, et al., “Effect of non-steroidal anti-inflammatory drugs on amyloid-$\beta$ formation and macrophage activation after platelet phagocytosis,” Journal of Cardiovascular Pharmacology, vol. 43, no. 3, pp. 462–470, 2004. View at Publisher · View at Google Scholar
126. G. R. Y. De Meyer, D. M. M. De Cleen, and S. Cooper, et al., “Platelet phagocytosis and processing of $\beta$-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis,” Circulation Research, vol. 90, no. 11, pp. 1197–1204, 2002. View at Publisher · View at Google Scholar
127. T. Nassar, B. S. Sachais, and S. Akkawi, et al., “Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells,” Journal of Biological Chemistry, vol. 278, no. 8, pp. 6187–6193, 2003. View at Publisher · View at Google Scholar · View at PubMed
128. M. Gawaz, K. Brand, and T. Dickfeld, et al., “Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis,” Atherosclerosis, vol. 148, no. 1, pp. 75–85, 2000. View at Publisher · View at Google Scholar
129. P. von Hundelshausen, K. S. Weber, and Y. Huo, et al., “RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium,” Circulation, vol. 103, no. 13, pp. 1772–1777, 2001.
130. C. Fernandez-Patron, M. A. Martinez-Cuesta, and E. Salas, et al., “Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2,” Thrombosis and Haemostasis, vol. 82, no. 6, pp. 1730–1735, 1999.
131. G. Sawicki, E. Salas, J. Murat, H. Miszta-Lane, and M. W. Radomski, “Release of gelatinase A during platelet activation mediates aggregation,” Nature, vol. 386, no. 6625, pp. 616–619, 1997. View at Publisher · View at Google Scholar · View at PubMed
132. A. E. May, T. Kälsch, S. Massberg, Y. Herouy, R. Schmidt, and M. Gawaz, “Engagement of glycoprotein IIb/IIIa (${\alpha }_{\text{IIb}}{\beta }_3$) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells,” Circulation, vol. 106, no. 16, pp. 2111–2117, 2002. View at Publisher · View at Google Scholar
133. S. Bellosta, D. Via, and M. Canavesi, et al., “HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 11, pp. 1671–1678, 1998.
134. S. W. Galt, S. Lindemann, and D. Medd, et al., “Differential regulation of matrix metalloproteinase-9 by monocytes adherent to collagen and platelets,” Circulation Research, vol. 89, no. 6, pp. 509–516, 2001. View at Publisher · View at Google Scholar
135. N. A. Turner, D. J. O'Regan, S. G. Ball, and K. E. Porter, “Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels,” The FASEB Journal, vol. 19, no. 7, pp. 804–806, 2005. View at Publisher · View at Google Scholar · View at PubMed
136. B. Wong, W. C. Lumma, A. M. Smith, J. T. Sisko, S. D. Wright, and T.-Q. Cai, “Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation,” Journal of Leukocyte Biology, vol. 69, no. 6, pp. 959–962, 2001.
137. S. Toomey, B. Harhen, H. M. Roche, D. Fitzgerald, and O. Belton, “Profound resolution of early atherosclerosis with conjugated linoleic acid,” Atherosclerosis, vol. 187, no. 1, pp. 40–49, 2006. View at Publisher · View at Google Scholar · View at PubMed
138. A. C. Li, C. J. Binder, and A. Gutierrez, et al., “Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPAR$\alpha$, $\beta /\delta$, and $\gamma$,” Journal of Clinical Investigation, vol. 114, no. 11, pp. 1564–1576, 2004. View at Publisher · View at Google Scholar · View at PubMed
139. Z. Chen, S. Ishibashi, and S. Perrey, et al., “Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 3, pp. 372–377, 2001.
140. A. C. Li, K. K. Brown, M. J. Silvestre, T. M. Willson, W. Palinski, and C. K. Glass, “Peroxisome proliferator-activated receptor $\gamma$ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice,” Journal of Clinical Investigation, vol. 106, no. 4, pp. 523–531, 2000. View at Publisher · View at Google Scholar
141. S. Cuzzocrea, B. Pisano, and L. Dugo, et al., “Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-$\gamma$, reduces acute pancreatitis induced by cerulein,” Intensive Care Medicine, vol. 30, no. 5, pp. 951–956, 2004. View at Publisher · View at Google Scholar · View at PubMed
142. H. Shu, B. Wong, and G. Zhou, et al., “Activation of PPAR$\alpha$ or $\gamma$ reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells,” Biochemical and Biophysical Research Communications, vol. 267, no. 1, pp. 345–349, 2000. View at Publisher · View at Google Scholar · View at PubMed
143. J. S. Sidhu, D. Cowan, J. A. Tooze, and J.-C. Kaski, “Peroxisome proliferator-activated receptor-$\gamma$ agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease,” American Heart Journal, vol. 147, no. 6, pp. 1032–1037, 2004. View at Publisher · View at Google Scholar · View at PubMed
144. F. F. Samaha, P. O. Szapary, and N. Iqbal, et al., “Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 3, pp. 624–630, 2006. View at Publisher · View at Google Scholar · View at PubMed
145. M. D. Leibowitz, C. Fiévet, and N. Hennuyer, et al., “Activation of PPAR$\delta$ alters lipid metabolism in db/db mice,” FEBS Letters, vol. 473, no. 3, pp. 333–336, 2000. View at Publisher · View at Google Scholar
146. J. N. van der Veen, J. K. Kruit, and R. Havinga, et al., “Reduced cholesterol absorption upon PPAR$\delta$ activation coincides with decreased intestinal expression of NPC1L1,” Journal of Lipid Research, vol. 46, no. 3, pp. 526–534, 2005. View at Publisher · View at Google Scholar · View at PubMed
147. A. Gallino, A. Haeberli, H. R. Baur, and P. W. Straub, “Fibrin formation and platelet aggregation in patients with severe coronary artery disease: relationship with the degree of myocardial ischemia,” Circulation, vol. 72, no. 1, pp. 27–30, 1985.
148. B. Ashby, J. L. Daniel, and J. B. Smith, “Mechanisms of platelet activation and inhibition,” Hematology/Oncology Clinics of North America, vol. 4, no. 1, pp. 1–26, 1990.
149. T. Ishizuka, S. Itaya, and H. Wada, et al., “Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism,” Diabetes, vol. 47, no. 9, pp. 1494–1500, 1998. View at Publisher · View at Google Scholar
150. M. Lorenz, S. Wessler, and E. Follmann, et al., “A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation,” Journal of Biological Chemistry, vol. 279, no. 7, pp. 6190–6195, 2004. View at Publisher · View at Google Scholar · View at PubMed
151. D. Li, K. Chen, and N. Sinha, et al., “The effects of PPAR-$\gamma$ ligand pioglitazone on platelet aggregation and arterial thrombus formation,” Cardiovascular Research, vol. 65, no. 4, pp. 907–912, 2005. View at Publisher · View at Google Scholar · View at PubMed
152. H. Kanehara, G. Tohda, K. Oida, J. Suzuki, H. Ishii, and I. Miyamori, “Thrombomodulin expression by THP-1 but not by vascular endothelial cells is upregulated by pioglitazone,” Thrombosis Research, vol. 108, no. 4, pp. 227–234, 2002. View at Publisher · View at Google Scholar
153. D. S. Calnek, L. Mazzella, S. Roser, J. Roman, and C. M. Hart, “Peroxisome proliferator-activated receptor $\gamma$ ligands increase release of nitric oxide from endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 1, pp. 52–57, 2003. View at Publisher · View at Google Scholar
154. D.-H. Cho, Y. J. Choi, S. A. Jo, and I. Jo, “Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) $\gamma$-dependent and PPAR$\gamma$-independent signaling pathways,” Journal of Biological Chemistry, vol. 279, no. 4, pp. 2499–2506, 2004. View at Publisher · View at Google Scholar · View at PubMed
155. H. Takano, T. Nagai, and M. Asakawa, et al., “Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-$\alpha$ expression in neonatal rat cardiac myocytes,” Circulation Research, vol. 87, no. 7, pp. 596–602, 2000.
156. T.-L. Yue, J. Chen, and W. Bao, et al., “In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-$\gamma$ agonist rosiglitazone,” Circulation, vol. 104, no. 21, pp. 2588–2594, 2001. View at Publisher · View at Google Scholar
157. J. E. Jordan, Z.-Q. Zhao, and J. Vinten-Johansen, “The role of neutrophils in myocardial ischemia-reperfusion injury,” Cardiovascular Research, vol. 43, no. 4, pp. 860–878, 1999. View at Publisher · View at Google Scholar
158. M. Ricote, J. T. Huang, J. S. Welch, and C. K. Glass, “The peroxisome proliferator-activated receptor$\gamma$ (PPAR$\gamma$) as a regulator of monocyte/macrophage function,” Journal of Leukocyte Biology, vol. 66, no. 5, pp. 733–739, 1999.
159. S. S. Huang, M. C. Tsai, C. L. Chih, L. M. Hung, and S. K. Tsai, “Resveratrol reduction of infarct size in Long-Evans rats subjected to focal cerebral ischemia,” Life Sciences, vol. 69, no. 9, pp. 1057–1065, 2001. View at Publisher · View at Google Scholar
160. D. L. Feinstein, “Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease,” Diabetes Technology & Therapeutics, vol. 5, no. 1, pp. 67–73, 2003. View at Publisher · View at Google Scholar · View at PubMed
161. R. Bordet, T. Ouk, and O. Petrault, et al., “PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases,” Biochemical Society Transactions, vol. 34, part 6, pp. 1341–1346, 2006. View at Publisher · View at Google Scholar · View at PubMed
162. S. Rios, “Relationship between obesity and the increased risk of major complications in non-insulin-dependent diabetes mellitus,” European Journal of Clinical Investigation, vol. 28, supplement 2, pp. 14–18, 1998. View at Publisher · View at Google Scholar
163. R. J. Gryglewski, R. M. Botting, and J. R. Vane, “Mediators produced by the endothelial cell,” Hypertension, vol. 12, no. 6, pp. 530–548, 1988.
164. G. Anfossi, E. M. Mularoni, and S. Burzacca, et al., “Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM,” Diabetes Care, vol. 21, no. 1, pp. 121–126, 1998. View at Publisher · View at Google Scholar
165. G. Anfossi, I. Russo, and P. Massucco, et al., “Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity,” European Journal of Clinical Investigation, vol. 34, no. 7, pp. 482–489, 2004. View at Publisher · View at Google Scholar · View at PubMed
166. T. Akai, K. Naka, K. Okuda, T. Takemura, and S. Fujii, “Decreased sensitivity of platelets to prostacyclin in patients with diabetes mellitus,” Hormone and Metabolic Research, vol. 15, no. 11, pp. 523–526, 1983. View at Publisher · View at Google Scholar
167. C. Falcon, G. Pfliegler, H. Deckmyn, and J. Vermylen, “The platelet insulin receptor: detection, partial characterizaztion, and search for a function,” Biochemical and Biophysical Research Communications, vol. 157, no. 3, pp. 1190–1196, 1988. View at Publisher · View at Google Scholar
168. M. Trovati, G. Anfossi, F. Cavalot, P. Massucco, E. Mularoni, and G. Emanuelli, “Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo,” Diabetes, vol. 37, no. 6, pp. 780–786, 1988. View at Publisher · View at Google Scholar
169. M. Udvardy, G. Pfliegler, and K. Rak, “Platelet insulin receptor determination in non-insulin dependent diabetes mellitus,” Cellular and Molecular Life Sciences, vol. 41, no. 3, pp. 422–423, 1985. View at Publisher · View at Google Scholar
170. N. N. Kahn, H. S. Mueller, and A. K. Sinha, “Restoration by insulin of impaired prostaglandin E1/I2 receptor activity of platelets in acute ischemic heart disease,” Circulation Research, vol. 68, no. 1, pp. 245–254, 1991.
171. B. Lipinski, “Pathophysiology of oxidative stress in diabetes mellitus,” Journal of Diabetes and its Complications, vol. 15, no. 4, pp. 203–210, 2001. View at Publisher · View at Google Scholar
172. J. V. Hunt, C. C. Smith, and S. P. Wolff, “Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose,” Diabetes, vol. 39, no. 11, pp. 1420–1424, 1990. View at Publisher · View at Google Scholar
173. W. E. Lands and R. J. Kulmacz, “The regulation of the biosynthesis of prostaglandins and leukotrienes,” Progress in Lipid Research, vol. 25, no. 1–4, pp. 105–109, 1986. View at Publisher · View at Google Scholar
174. M. Lagarde, “Metabolism of fatty acids by platelets and the functions of various metabolites in mediating platelet function,” Progress in Lipid Research, vol. 27, no. 2, pp. 135–152, 1988. View at Publisher · View at Google Scholar
175. E. Véricel, C. Januel, M. Carreras, P. Moulin, and M. Lagarde, “Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status,” Diabetes, vol. 53, no. 4, pp. 1046–1051, 2004.
176. C. Calzada, E. Véricel, B. Mitel, L. Coulon, and M. Lagarde, “12(S)-hydroperoxy-eicosatetraenoic acid increases arachidonic acid availability in collagen-primed platelets,” Journal of Lipid Research, vol. 42, no. 9, pp. 1467–1473, 2001.
177. D. Tschoepe, U. Rauch, and B. Schwippert, “Platelet-leukocyte-cross-talk in diabetes mellitus,” Hormone and Metabolic Research, vol. 29, no. 12, pp. 631–635, 1997. View at Publisher · View at Google Scholar
178. H. Lee, R. C. Paton, P. Passa, and J. P. Caen, “Fibrinogen binding and ADP-induced aggregation in platelets from diabetic subjects,” Thrombosis Research, vol. 24, no. 1-2, pp. 143–150, 1981. View at Publisher · View at Google Scholar
179. P. V. Halushka, R. C. Rogers, C. B. Loadholt, and J. A. Colwell, “Increased platelet thromboxane synthesis in diabetes mellitus,” Journal of Laboratory and Clinical Medicine, vol. 97, no. 1, pp. 87–96, 1981.
180. R. K. Mayfield, P. V. Halushka, and H. J. Wohltmann, et al., “Platelet function during continuous insulin infusion treatment in insulin-dependent diabetic patients,” Diabetes, vol. 34, no. 11, pp. 1127–1133, 1985. View at Publisher · View at Google Scholar
181. N. Marx, A. Imhof, and J. Froehlich, et al., “Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease,” Circulation, vol. 107, no. 15, pp. 1954–1957, 2003. View at Publisher · View at Google Scholar · View at PubMed
182. R. Stienstra, C. Duval, M. Müller, and S. Kersten, “PPARs, obesity, and inflammation,” PPAR Research, vol. 2007, Article ID 95974, 10 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
183. P. Trayhurn and I. S. Wood, “Signalling role of adipose tissue: adipokines and inflammation in obesity,” Biochemical Society Transactions, vol. 33, part 5, pp. 1078–1081, 2005. View at Publisher · View at Google Scholar · View at PubMed
184. Y.-H. Yu and H. N. Ginsberg, “Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue,” Circulation Research, vol. 96, no. 10, pp. 1042–1052, 2005. View at Publisher · View at Google Scholar · View at PubMed
185. R. Jones, “Nonsteroidal anti-inflammatory drug prescribing: past, present, and future,” The American Journal of Medicine, vol. 110, no. 1, supplement 1, pp. S4–S7, 2001. View at Publisher · View at Google Scholar
186. G. J. Hankey and J. W. Eikelboom, “Aspirin resistance,” British Medical Journal, vol. 328, no. 7438, pp. 477–479, 2004. View at Publisher · View at Google Scholar · View at PubMed
187. J. A. Cambria-Kiely and P. J. Gandhi, “Aspirin resistance and genetic polymorphisms,” Journal of Thrombosis and Thrombolysis, vol. 14, no. 1, pp. 51–58, 2002. View at Publisher · View at Google Scholar
188. A. Szczeklik, J. Musiał, A. Undas, and M. Sanak, “Aspirin resistance,” Journal of Thrombosis and Haemostasis, vol. 3, no. 8, pp. 1655–1662, 2005. View at Publisher · View at Google Scholar · View at PubMed
189. D. M. Becker, J. Segal, and D. Vaidya, et al., “Sex differences in platelet reactivity and response to low-dose aspirin therapy,” Journal of the American Medical Association, vol. 295, no. 12, pp. 1420–1427, 2006. View at Publisher · View at Google Scholar · View at PubMed
190. D. L. Bhatt, K. A. A. Fox, and W. Hacke, et al., “Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events,” The New England Journal of Medicine, vol. 354, no. 16, pp. 1706–1717, 2006. View at Publisher · View at Google Scholar · View at PubMed
191. D. L. Bhatt and E. J. Topol, “Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) trial,” American Heart Journal, vol. 148, no. 2, pp. 263–268, 2004. View at Publisher · View at Google Scholar · View at PubMed
192. C. L. Bennett, J. M. Connors, and J. M. Carwile, et al., “Thrombotic thrombocytopenic purpura associated with clopidogrel,” The New England Journal of Medicine, vol. 342, no. 24, pp. 1773–1777, 2000. View at Publisher · View at Google Scholar
193. S. R. Steinhubl, W. A. Tan, J. M. Foody, and E. J. Topol, “Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting,” Journal of the American Medical Association, vol. 281, no. 9, pp. 806–810, 1999. View at Publisher · View at Google Scholar
194. D. P. Chew and D. L. Bhatt, “Oral glycoprotein IIb/IIIa antagonists in coronary artery disease,” Current Cardiology Reports, vol. 3, no. 1, pp. 63–71, 2001. View at Publisher · View at Google Scholar
195. D. P. Chew, D. L. Bhatt, S. Sapp, and E. J. Topol, “Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials,” Circulation, vol. 103, no. 2, pp. 201–206, 2001.
196. E. S. Tai, D. Collins, and S. J. Robins, et al., “The L162V polymorphism at the peroxisome proliferator activated receptor $\alpha$ locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT),” Atherosclerosis, vol. 187, no. 1, pp. 153–160, 2006. View at Publisher · View at Google Scholar · View at PubMed
197. A. Keech, R. J. Simes, and P. Barter, et al., “Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial,” The Lancet, vol. 366, no. 9500, pp. 1849–1861, 2005. View at Publisher · View at Google Scholar · View at PubMed
198. B. Staels and J.-C. Fruchart, “Therapeutic roles of peroxisome proliferator-activated receptor agonists,” Diabetes, vol. 54, no. 8, pp. 2460–2470, 2005. View at Publisher · View at Google Scholar
199. F. Blaschke, Y. Takata, E. Caglayan, R. E. Law, and W. A. Hsueh, “Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 1, pp. 28–40, 2006. View at Publisher · View at Google Scholar · View at PubMed
200. P. Biswas, L. V. Wilton, and S. A. Shakir, “Troglitazone and liver function abnormalities: lessons from a prescription event monitoring study and spontaneous reporting,” Drug Safety, vol. 24, no. 2, pp. 149–154, 2001. View at Publisher · View at Google Scholar
201. “Troglitazone withdrawn from market,” American Journal of Health-System Pharmacy, vol. 57, no. 9, p. 834, 2000.
202. B. K. Irons, R. S. Greene, T. A. Mazzolini, K. L. Edwards, and R. B. Sleeper, “Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus,” Pharmacotherapy, vol. 26, no. 2, pp. 168–181, 2006. View at Publisher · View at Google Scholar · View at PubMed
203. J. A. Dormandy, B. Charbonnel, and D. J. Eckland, et al., “Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial,” The Lancet, vol. 366, no. 9493, pp. 1279–1289, 2005. View at Publisher · View at Google Scholar · View at PubMed
204. S. M. Haffner, A. S. Greenberg, W. M. Weston, H. Chen, K. Williams, and M. I. Freed, “Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus,” Circulation, vol. 106, no. 6, pp. 679–684, 2002. View at Publisher · View at Google Scholar
205. S. E. Kahn, S. M. Haffner, and M. A. Heise, et al., “Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy,” The New England Journal of Medicine, vol. 355, no. 23, pp. 2427–2443, 2006. View at Publisher · View at Google Scholar · View at PubMed
206. A. J. Scheen, “DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease,” Revue Medicale de Liege, vol. 61, no. 10, pp. 728–732, 2006.
207. P. D. Home, S. J. Pocock, and H. Beck-Nielsen, et al., “Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis,” The New England Journal of Medicine, vol. 357, no. 1, pp. 28–38, 2007. View at Publisher · View at Google Scholar · View at PubMed
208. T.-A. Cock, S. M. Houten, and J. Auwerx, “Peroxisome proliferator-activated receptor-$\gamma$: too much of a good thing causes harm,” EMBO Reports, vol. 5, no. 2, pp. 142–147, 2004. View at Publisher · View at Google Scholar · View at PubMed
209. S. M. Rangwala and M. A. Lazar, “The dawn of the SPPARMs?,” Science's STKE, vol. 2002, no. 121, p. pe9, 2002. View at Publisher · View at Google Scholar · View at PubMed
210. P. V. Devasthale, S. Chen, and Y. Jeon, et al., “Discovery of tertiary aminoacids as dual PPAR$\alpha /\gamma$ agonists-I,” Bioorganic & Medicinal Chemistry Letters, vol. 17, no. 8, pp. 2312–2316, 2007. View at Publisher · View at Google Scholar · View at PubMed
211. P. V. Devasthale, S. Chen, and Y. Jeon, et al., “Design and synthesis of $N$-[(4-methoxyphenoxy)carbonyl]-$N$-[[4-[2-(5-methyl- 2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor $\alpha /\gamma$ dual agonist with efficacious glucose and lipid-lowering activities,” Journal of Medicinal Chemistry, vol. 48, no. 6, pp. 2248–2250, 2005. View at Publisher · View at Google Scholar · View at PubMed
212. T. Hatae, M. Wada, C. Yokoyama, M. Shimonishi, and T. Tanabe, “Prostacyclin-dependent apoptosis mediated by PPAR$\delta$,” Journal of Biological Chemistry, vol. 276, no. 49, pp. 46260–46267, 2001. View at Publisher · View at Google Scholar · View at PubMed
213. R. Hertz, I. Berman, D. Keppler, and J. Bar-Tana, “Activation of gene transcription by prostacyclin analogues is mediated by the peroxisome-proliferators-activated receptor (PPAR),” European Journal of Biochemistry, vol. 235, no. 1-2, pp. 242–247, 1996. View at Publisher · View at Google Scholar
214. H. Lim and S. K. Dey, “PPAR$\delta$ functions as a prostacyclin receptor in blastocyst implantation,” Trends in Endocrinology and Metabolism, vol. 11, no. 4, pp. 137–142, 2000. View at Publisher · View at Google Scholar